Cancer Policy FDA approves labeling changes to menopausal hormone therapy products February 13, 2026Vol.52 No.06By Claire Marie Porter
Cancer Policy HHS withdraws 340B drug rebate pilot program February 13, 2026Vol.52 No.06By Sara Willa Ernst
Cancer Policy NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism February 06, 2026Vol.52 No.05By Sara Willa Ernst
Cancer Policy “Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden February 06, 2026Vol.52 No.05By Jacquelyn Cobb
Cancer Policy FDA debuts precheck manufacturing program to boost domestic drug development February 06, 2026Vol.52 No.05By Claire Marie Porter
Cancer Policy NIH suspends new embryonic stem cell line submissions January 30, 2026Vol.52 No.04By Sara Willa Ernst
Cancer Policy CMS to enter negotiations with drugmakers over the price of four cancer medications January 30, 2026Vol.52 No.04By Sara Willa Ernst
Cancer Policy Tens of thousands of healthcare workers strike across the country January 30, 2026Vol.52 No.04By Sara Willa Ernst
Cancer Policy FDA delays drug reviews in new voucher program amid safety, efficacy concerns January 30, 2026Vol.52 No.04By Claire Marie Porter
